Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "lymphomas"

24 News Found

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors
Drug Approval | August 13, 2022

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors

Company creates Younger T Cells for fighting cancer using its NR2F6 technology

USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma
Biotech | April 03, 2022

USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma

Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --

Moderna presents data from Phase 1 study of mRNA Triplet programme
Biotech | November 13, 2021

Moderna presents data from Phase 1 study of mRNA Triplet programme

The interim data combines three mRNAs into one therapy injected directly into the tumour

Aurobindo subsidiary, Eugia gets US FDA approval for Cyclophosphamide injection
Drug Approval | August 27, 2021

Aurobindo subsidiary, Eugia gets US FDA approval for Cyclophosphamide injection

The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

Teva submits FDA application for experimental Tourette syndrome treatment ecopipam

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging